Prelude Therapeutics Inc. — Q1 2022 Form 10-Q
Reporting period: Three months ended March 31, 2022; compared with the three months ended March 31, 2021. Prelude is a clinical-stage oncology company with no product revenue and no approved products.
Financial performance and position
| Metric | Q1 2022 | Q1 2021 | Change |
|---|---|---|---|
| Revenue | None | None | No revenue in either period |
| Research and development expense | $22.8 million | $16.5 million | Up $6.4 million |
| General and administrative expense | $7.5 million | $5.5 million | Up $2.0 million |
| Total operating expenses | $30.3 million | $22.0 million | Up $8.3 million |
| Net loss | $29.5 million | $21.3 million | Loss increased $8.2 million |
| Net loss per share, basic and diluted | $0.63 | $0.47 | Loss per share increased |
| Cash used in operating activities | $21.9 million | $16.1 million | Use increased $5.8 million |
Operating margins are not meaningful because the company has no revenue. Other income, net was $0.8 million, versus $0.7 million, including interest and Delaware grant income. Stock-based compensation was $6.8 million, compared with $3.9 million.
At March 31, 2022, cash and cash equivalents were $51.6 million and marketable securities were $214.6 million, totaling $266.2 million; restricted cash of $4.0 million was additional. Current assets were $270.0 million and current liabilities were $16.1 million. Total liabilities were $18.9 million. The filing reports no credit facility or committed sources of capital and presents no borrowings. Accumulated deficit was $248.6 million.
Cash, cash equivalents and marketable securities declined by $25.0 million from December 31, 2021, while cash and cash equivalents alone increased, partly reflecting $42.5 million of investment maturities. Investing activities provided $41.5 million; financing activities provided $0.2 million. The $1.6 million unrealized loss on available-for-sale securities reduced comprehensive results and was recorded in other comprehensive loss, not net loss.
Material changes versus Q1 2021
- Operating expenses rose 38%, led by higher discovery-stage spending, pipeline advancement, chemistry and manufacturing costs, personnel costs, and stock-based compensation.
- R&D program costs increased for discovery programs ($5.4 million versus $2.1 million) and internal costs ($11.2 million versus $6.3 million). PRT543 expenses decreased to $0.9 million from $3.3 million.
- Operating cash use increased as the net loss widened. Q1 2021 financing included $161.4 million of net proceeds from a common-stock offering; there was no comparable offering in Q1 2022.
- Marketable securities had $2.3 million of gross unrealized losses at quarter-end, versus $0.7 million at year-end 2021. Management considered the losses temporary and expected recovery at maturity.
Outlook, management commentary and risks
- Management expects existing cash, cash equivalents and marketable securities to fund operating expenses and capital expenditures into the second half of 2024. This estimate depends on assumptions and may prove inaccurate; additional funding will be needed thereafter unless revenue or other financing is obtained.
- Management expects significant ongoing losses and increasing R&D and G&A expenses. The company does not expect product-sales revenue in the foreseeable future.
- Clinical priorities include focusing PRMT5 development on selected populations, with further PRT811 expansion-cohort analysis targeted by mid-year and next-step decisions expected in the second half of 2022. The company prioritized intravenous PRT1419 and planned to evaluate combinations by mid-year, aiming for a recommended Phase 2 dose in the second half. It also targeted completion of PRT2527 Phase 1 dose-escalation enrollment in the second half.
- For preclinical programs, management intended to complete PRT3645 IND-enabling work, file an IND and start a Phase 1 trial in the second half of 2022, and submit an IND for its SMARCA2 degrader program by year-end. These are plans, not assurances.
- The filing says lead programs and research activities remained on track, while also disclosing limited COVID-19-related delays in some site initiations, patient participation and enrollment. Further trial, vendor, enrollment and data-collection disruptions remain possible.
- Key risks include early-stage clinical uncertainty, safety and efficacy outcomes, competition for patients, reliance on CROs and third-party manufacturers (including single-source suppliers), financing needs, intellectual-property challenges and market volatility. Management reported no material legal proceedings and no material change in internal control over financial reporting; disclosure controls were deemed effective at a reasonable assurance level.
- Lease and grant items: the Wilmington office lease was extended through June 30, 2023. The Chestnut Run lease covers approximately 81,000 square feet, has a 162-month initial term and estimated initial-term rent of about $33.8 million; commencement remained conditional. The company received $2.4 million in state grant cash for lab-space development, recorded as a long-term liability pending recognition over related asset lives, and recognized $0.3 million of grant income for meeting a performance benchmark. Grant repayment conditions apply.
Important facts for investors to verify
- Cash runway assumptions and the timing, terms and dilution implications of future financing.
- Current clinical status, enrollment, safety and efficacy data for PRT543, PRT811, PRT1419 and PRT2527, and whether planned 2022 milestones were achieved.
- Whether COVID-19, trial-site capacity, patient recruitment, CROs or manufacturing constraints have changed development timelines or costs.
- Cash-flow trajectory, R&D spending growth, stock-based compensation and the market value and credit quality of the securities portfolio.
- Chestnut Run lease commencement and obligations, and compliance with Delaware grant spending, location and employee benchmarks.
- The filing describes four candidates advanced into clinical trials in its overview, while other passages refer to three clinical-stage candidates. Confirm the company’s intended pipeline count and status.